Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03110575 · ClinicalTrials.gov registry record · Phase 3
12-Week Open-Label Extension Study of TNX-102 SL in PTSD Patients
A Phase 3 study, sponsored by Tonix Pharmaceuticals.
- Terminated
- Registry status
- Phase 3
- Development phase
- 190
- Enrollment target
NCT03110575 is a Phase 3 study that was terminated before completion, run by Tonix Pharmaceuticals. The registered enrollment target is 190 participants.
The verdict
NCT03110575, a Phase 3 study, was terminated before completion, sponsored by Tonix Pharmaceuticals.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 190 participants
- Enrollment target
Study Summary
This is an open-label, extension trial designed to evaluate safety over 12 additional weeks of TNX-102 SL therapy taken daily at bedtime for the treatment of PTSD. Patients recruited into this trial are those who have successfully completed the double-blind lead-in study.
Interventions
- DRUG TNX-102 SL
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 190 participants |
| Start Date | 2017-06-20 |
| Est. Completion | 2018-07-27 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03110575
The ClinicalTrials.gov registry entry for NCT03110575 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 190 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Tonix Pharmaceuticals, which has 23 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which TNX-102 SL is the first listed.
NCT03110575 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03110575 about?
NCT03110575 is a clinical study titled "12-Week Open-Label Extension Study of TNX-102 SL in PTSD Patients". This is an open-label, extension trial designed to evaluate safety over 12 additional weeks of TNX-102 SL therapy taken daily at bedtime for the treatment of PTSD. Patients recruited into this trial are those who have successfully completed the double-blind lead-in study.
What is the current status of trial NCT03110575?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 190 participants. The study started on 2017-06-20. Estimated completion is 2018-07-27.
What interventions are being tested in trial NCT03110575?
The interventions under investigation include: TNX-102 SL (DRUG).
Who is sponsoring clinical trial NCT03110575?
This trial is sponsored by Tonix Pharmaceuticals, which has 23 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.